| Literature DB >> 18445528 |
Hyun-Soon Chong1, Hyun A Song, Noah Birch, Thien Le, Sooyoun Lim, Xiang Ma.
Abstract
The efficient and short synthetic route to the structurally novel bimodal ligand NETA for antibody-targeted radiation therapy (radioimmunotherapy, RIT) of cancer was developed. The structure of NETA was determined by X-ray crystallography. The arsenazo-based UV spectroscopic complexation kinetics data suggest that NETA is a promising chelator for use in RIT applications of (212)Bi, (213)Bi, and (177)Lu.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18445528 DOI: 10.1016/j.bmcl.2008.03.084
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823